No Data
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
Watchlist
70.180
-0.050-0.07% Close 12/08 16:00 ET
70.1800.0000.00%
Post 16:01 ET
72.780High69.400Low1.36MVolume
70.970Open70.230Pre Close95.65MTurnover3.90%Turnover RatioLossP/E (TTM)3.32BMarket Cap91.29052wk HighLossP/E (Static)47.32MShares53.71052wk Low12.32P/B2.44BFloat Cap109.940Historical High--Dividend TTM34.83MShs Float1.940Historical Low--Div YieldTTM4.81%Amplitude70.424Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Axsome Therapeutics Company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Single Segment50.04M100.00%
News
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event With Expert Thought Leaders Today
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), OrthoPediatrics (KIDS) and Axsome Therapeutics (AXSM)
Smoking Cessation Market to Grow at a Substantial Growth Rate During the Forecast Period (2023–2032), Assesses DelveInsight | Key Companies - Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics
New York, USA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Smoking Cessation Market to Grow at a Substantial Growth Rate During the Forecast Period (2023–2032), Assesses DelveInsight | Key Companies - Axsome Therapeutics,
Comments
Axsome Therapeutics' 66% projected growth rate may be overly optimistic. A slower growth rate might push the break-even point further, and the high debt level of 63% of its equity amplifies the investment risk in the unprofitable company.
Breakeven On The Horizon For Axsome Therapeutics, Inc. (NASDAQ:AXSM)
ColumnsToday's Pre-Market Stock Movers And Top Ratings: SGMT, LLY, CHGG, BYND and More
Pre-Market Stock Movers
Gapping up
$Sagimet Biosciences(SGMT.US$
(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.）
$Eli Lilly and Co(LLY.US$
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
Gapping up
$Sagimet Biosciences(SGMT.US$
(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.）
$Eli Lilly and Co(LLY.US$
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...
15
1
TOP WATCH 7/3 ⚡️⚡️
follow for daily top watchlist ⭐️
$Apyx Medical(APYX.US$$Addentax(ATXG.US$$Axsome Therapeutics(AXSM.US$$BioXcel Therapeutics(BTAI.US$$Baudax Bio(BXRX.US$$CymaBay Therapeutics(CBAY.US$$CorMedix(CRMD.US$$Marriott International(MAR.US$$Microvision(MVIS.US$$Renalytix(RNLX.US$$State Street(STT.US$$Treehouse Foods(THS.US$$Targa Resources(TRGP.US$$VBI Vaccines(VBIV.US$$Ventas Inc(VTR.US$
$Apyx Medical(APYX.US$$Addentax(ATXG.US$$Axsome Therapeutics(AXSM.US$$BioXcel Therapeutics(BTAI.US$$Baudax Bio(BXRX.US$$CymaBay Therapeutics(CBAY.US$$CorMedix(CRMD.US$$Marriott International(MAR.US$$Microvision(MVIS.US$$Renalytix(RNLX.US$$State Street(STT.US$$Treehouse Foods(THS.US$$Targa Resources(TRGP.US$$VBI Vaccines(VBIV.US$$Ventas Inc(VTR.US$
1
ColumnsA list of companies with deposits in SVB
Based on comprehensive media reports, I compiled a list of some institutions with deposits in the bank for your reference.$SVB Financial(SIVB.US$
ROKU: 26% cash, $487 million in Silicon Valley Bank.$Roku Inc(ROKU.US$
BLOCKFI: According to a bankruptcy filing, BlockFi has $227 million in "unprotected" funds at Silicon Valley Bank, possibly in violation of U.S. bankruptcy law.
RBLX: Roblox says 5% of its $3 billion cash and securities balance is held by S...
ROKU: 26% cash, $487 million in Silicon Valley Bank.$Roku Inc(ROKU.US$
BLOCKFI: According to a bankruptcy filing, BlockFi has $227 million in "unprotected" funds at Silicon Valley Bank, possibly in violation of U.S. bankruptcy law.
RBLX: Roblox says 5% of its $3 billion cash and securities balance is held by S...
3
1
ColumnsToday's Pre-Market Stock Movers: DAL, TSM, DPZ, AMAT and More
Gapping up
In reaction to earnings/guidance:
• $Constellation Energy(CEG.US$ +8.2%,$Walgreens Boots Alliance(WBA.US$ +6.8%,$QuidelOrtho(QDEL.US$ +6.7% (guides Q3 revs well above consensus),$Domino's Pizza(DPZ.US$ +5.9%,$Delta Air Lines(DAL.US$ +4.2%,$Commercial Metals(CMC.US$ +3.5%,$Victoria's Secret(VSCO.US$ +3.3%,$Taiwan Semiconductor(TSM.US$ +2.6%
Other news:
• $Axsome Therapeutics(AXSM.US$ +12.2% (trading h...
In reaction to earnings/guidance:
• $Constellation Energy(CEG.US$ +8.2%,$Walgreens Boots Alliance(WBA.US$ +6.8%,$QuidelOrtho(QDEL.US$ +6.7% (guides Q3 revs well above consensus),$Domino's Pizza(DPZ.US$ +5.9%,$Delta Air Lines(DAL.US$ +4.2%,$Commercial Metals(CMC.US$ +3.5%,$Victoria's Secret(VSCO.US$ +3.3%,$Taiwan Semiconductor(TSM.US$ +2.6%
Other news:
• $Axsome Therapeutics(AXSM.US$ +12.2% (trading h...
9
ColumnsToday's Pre-Market Stock Movers: KMX, RAD, BBBY, MTN and More
Gapping up
In reaction to earnings/guidance:
• $Vail Resorts(MTN.US$ +3.7%,$The Duckhorn Portfolio(NAPA.US$ +2.7%,$Jefferies Financial(JEF.US$ +1.6%
Other news:
• $Axsome Therapeutics(AXSM.US$ +4.3% (disclosesplansto resubmit AXS-07 NDA basedonsuccessfulFDAtype a meeting)
• $Invivyd(IVVD.US$ +4.1% (files for $400mlnmixed securities shelf offering)
• $TRITIUM DCFC LIMITED(DCFC.US$ +3.1%(tosupply fast chargers for Australia's l...
In reaction to earnings/guidance:
• $Vail Resorts(MTN.US$ +3.7%,$The Duckhorn Portfolio(NAPA.US$ +2.7%,$Jefferies Financial(JEF.US$ +1.6%
Other news:
• $Axsome Therapeutics(AXSM.US$ +4.3% (disclosesplansto resubmit AXS-07 NDA basedonsuccessfulFDAtype a meeting)
• $Invivyd(IVVD.US$ +4.1% (files for $400mlnmixed securities shelf offering)
• $TRITIUM DCFC LIMITED(DCFC.US$ +3.1%(tosupply fast chargers for Australia's l...
12
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Joe Biden is launching a new initiative to encourage biotech production and research in the U.S. On Monday, he signed an executive order implementing the initiative and later will address how biotech can help fight cancer, though the amount of funding the White House is setting aside for it is unclear.
What This Means for Biotech Stocks
This isn’t the first time that President Biden has zeroed in on the biotech sect...
What This Means for Biotech Stocks
This isn’t the first time that President Biden has zeroed in on the biotech sect...
14
3
1
2
News Brief and Analyst Updates
Follow to get my Chart Analysis on the tickers below.
$Volcon(VLCN.US$- "Volcon Obtains Pre-Orders that Sells Out Entire 2023 Forecast;
$100M+ of Potential Revenue"
$Eargo(EAR.US$
- "Eargo Supports Over-the-Counter Hearing Aid Final Ruling"
- "CFO, said, “This ruling directly aligns with Eargo’s mission. By making hearing aids more accessible..."
$Axsome Therapeutics(AXSM.US$
- "Axsomes depression drug receives FDA approval"
- "Ladenburg Reiterates b...
Follow to get my Chart Analysis on the tickers below.
$Volcon(VLCN.US$- "Volcon Obtains Pre-Orders that Sells Out Entire 2023 Forecast;
$100M+ of Potential Revenue"
$Eargo(EAR.US$
- "Eargo Supports Over-the-Counter Hearing Aid Final Ruling"
- "CFO, said, “This ruling directly aligns with Eargo’s mission. By making hearing aids more accessible..."
$Axsome Therapeutics(AXSM.US$
- "Axsomes depression drug receives FDA approval"
- "Ladenburg Reiterates b...
3
ColumnsToday's Pre-Market Stock Movers: FL, DE, BBBY, AMC and More
Gainers:
In reaction to earnings/guidance:
• $Foot Locker(FL.US$ +19.7%,$BILL Holdings(BILL.US$ +18.1% (also names new COO),$Buckle Inc(BKE.US$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
In reaction to earnings/guidance:
• $Foot Locker(FL.US$ +19.7%,$BILL Holdings(BILL.US$ +18.1% (also names new COO),$Buckle Inc(BKE.US$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
13
1
ColumnsToday's pre-market stock movers: BNTX, JBLU, DWAC, SAVE and more
Gainers:
• $Axsome Therapeutics(AXSM.US$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics(CAPR.US$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
• $Axsome Therapeutics(AXSM.US$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics(CAPR.US$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
14
2
ColumnsToday's pre-market stock movers: CRM, WB, LI, NIO and more
Gainers:
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
21
ColumnsToday's pre-market stock movers: JELD, BILI, NIO, XPEV and more
Gainers：
• $Innoviz Technologies(INVZ.US$ +18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands)
• $Hilltop Holdings(HTH.US$ +15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
• $Innoviz Technologies(INVZ.US$ +18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands)
• $Hilltop Holdings(HTH.US$ +15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
18
3
$Axsome Therapeutics(AXSM.US$
Sunosi was approved by the U.S. Food and Drug Administration (FDA) in 2019 and by the European Medicines Agency (EMA) in 2020. Sunosi is the first and only DNRI approved to treat EDS in adults living with narcolepsy or OSA. Sunosi net sales were $57.9 million in 2021, representing year-over-year growth of 104%. In addition to further growth potential in the current indication for Sunosi, there are opportunities to pursue new high-value indications in psychiatry a...
Sunosi was approved by the U.S. Food and Drug Administration (FDA) in 2019 and by the European Medicines Agency (EMA) in 2020. Sunosi is the first and only DNRI approved to treat EDS in adults living with narcolepsy or OSA. Sunosi net sales were $57.9 million in 2021, representing year-over-year growth of 104%. In addition to further growth potential in the current indication for Sunosi, there are opportunities to pursue new high-value indications in psychiatry a...
1
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--